Quanterix Gears Up for IPO
Life sciences company Quanterix intends to price more than 3 million shares in a range that results in an initial public offering valued up to more than $61 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 151
Revance Scores Solid Results in Late-Stage Trial
Shares of Revance Therapeutics saw a solid gain early on Tuesday after the company announced positive top-line results from its late-stage trials.
Jefferies Has 4 Red-Hot Biotech Stock Picks for December
These four momentum biotech plays still have solid upside to the Jefferies price targets and would be solid additions to aggressive accounts with higher risk tolerance.
Why Apple Is Propping Up BioTelemetry
BioTelemetry saw its shares make a handy gain on Thursday after a new partnership with Apple to provide cardiac monitoring services in conjunction with the Apple Heart Study.
Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
Apollo Endosurgery Surges on FDA Approval
Shares of Apollo Endosurgery saw a healthy gain early on Tuesday after the company announced it had received 510k clearance from the FDA for its OverStitch Sx.
Will Teva’s Restructuring Stop the Bleeding?
Shares of Teva Pharmaceutical Industries rose Monday after the company announced a reorganization some of its top leadership positions.
Odonate Therapeutics Gears Up for IPO
Odonate Therapeutics expects to price more than 5 million shares in a range that results in an initial public offering valued up to more than $182 million.
NVIDIA, GE Healthcare Strike Deal on AI
General Electric's Healthcare segment signed a deal Sunday with Nvidia to use the chipmaker's artificial intelligence platform. GE Healthcare also inked a deal with Intel Monday morning.
Alkermes Could Win Big With New Biogen Partnership
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.
Denali Therapeutics Announces Potential Pricing for IPO
Neurodegenerative disease focused Denali Therapeutics intends to price more than 8 million shares in a range that results in an initial offering valued up to about $182 million.
Why Celsion Could Still More Than Double on Top of Good News
Celsion Corp. (NASDAQ: CLSN) watched its shares make an incredible gain on Tuesday after it received an even bigger upgrade from Oppenheimer. This came on the heels of new findings in its Liver Tumours…
Cytokinetics Crumbles on Late-Stage Results
Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesday’s session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firm’s Phase 3…
Summit Therapeutics Closes in on DMD Results
Summit Therapeutics PLC (NASDAQ: SMMT) saw its shares make a handy gain on Monday after the firm announced that it had completed the dosing for the patients in its Duchenne muscular dystrophy (DMD) trial.
Achillion Pharmaceuticals Gears Up for Secondary Offering
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.